Phase II Study of Asciminib for Second-line Treatment of Chronic Phase Chronic Myeloid Leukemia

Part of paid clinical trials in Houston, Texas.

Sponsor
M.D. Anderson Cancer Center
Study ID
NCT06629584
Phase
PHASE2
Status
Recruiting
Apply to this trial

Conditions

  • Malignant Solid Tumors

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • Asciminib — DRUG
    Patients will receive asciminib 80 mg PO once daily continuously for 28-day cycles for 2 years.

Study Details

This is an open label, phase 2 study investigating asciminib in patients previously treated with one line of TKI therapy.

Key Dates

Start date
Feb 14, 2025
Status verified
Jun 2026
Primary completion
Dec 31, 2026
Completion
Dec 31, 2028

Study Design

Enrollment
40 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: Asciminib
    Patients will receive asciminib 80 mg once daily continuously for 28-day cycles for 2 years.

Primary Outcome Measure

Major molecular response (MMR) rate by 12 months [ Time Frame: at 12 months of therapy ]

Central Contacts

Locations (1)

FacilityCityStateZIPSite coordinators
The University of Texas MD Anderson Cancer CenterHoustonTexas77030
Ghayas Issa, MD
[email protected]
713-745-6798
Ghayas Issa, MD (PRINCIPAL_INVESTIGATOR)

Find similar trials in Houston, TX

By research site
The University of Texas MD Anderson Cancer Center· Houston, TX

Related Studies